These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1379578)

  • 21. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
    Hermann GG; Petersen KR; Steven K; Zeuthen J
    J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
    Kikuchi T; Watanabe M; Ohno T
    Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules.
    Chong AS; Boussy IA; Graf LH; Scuderi P
    Cell Immunol; 1992 Oct; 144(1):69-79. PubMed ID: 1356634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody.
    Azuma A; Yagita H; Okumura K; Kudoh S; Niitani H
    Cancer Immunol Immunother; 1994 May; 38(5):294-8. PubMed ID: 7909278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
    Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
    Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in natural immunity during the course of HIV-1 infection.
    Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
    Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.
    Zhu HG; Zollner TM; Klein-Franke A; Anderer FA
    J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
    Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A
    Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
    Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of human B cell responsiveness by CD8+ T cells: differential effects of stimulation with monoclonal antibodies to CD3 and pokeweed mitogen.
    Hirohata S; Patel SS; Lipsky PE
    Cell Immunol; 1990 Apr; 127(1):35-46. PubMed ID: 2138519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors.
    Ballas ZK; Rasmussen W
    Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
    Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
    J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
    Hirte HW; Clark DA; O'Connell G; Rusthoven J; Mazurka J
    Cell Immunol; 1992 Jun; 142(1):207-16. PubMed ID: 1534038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.
    Ferrarini M; Ferrero E; Fortis C; Poggi A; Zocchi MR
    Br J Cancer; 1990 Nov; 62(5):754-7. PubMed ID: 1700922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomagnetic isolation of NK and LAK cells.
    Naume B; Nonstad U; Steinkjer B; Funderud S; Smeland E; Espevik T
    J Immunol Methods; 1991 Jan; 136(1):1-9. PubMed ID: 1704900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.